OTC TOPICAL ERYTHROMYCIN WOULD LEAD TO INCREASED BACTERIAL RESISTANCE
This article was originally published in The Tan Sheet
Executive Summary
OTC TOPICAL ERYTHROMYCIN WOULD LEAD TO INCREASED BACTERIAL RESISTANCE to the antibiotic, a joint FDA advisory committee unanimously agreed on Nov. 16. Members of FDA's Dermatologic & Ophthalmic Drugs, Anti-Infective Drugs and Nonprescription Drags Advisory Committees voted 15-0 that switching topical erythromycin to over-the-counter status for the treatment of acne would lead to increased bacterial resistance to the drug.